Clinical studies have demonstrated that GLP-1 receptor agonists reduce body weight and visceral and hepatic fat deposits, and also improve hepatic insulin sensitivity in obese patients with T2DM [18, 25–27]. Here, INS is linked to type 2 diabetes mellitus.